Introduction/Background Undifferentiated endometrial sarcoma (ues) is a rare histological subtype of uterine sarcoma with a poor prognosis. This study aimed to assess the clinical presentation and the outcome of ues.

Methodology We conducted a monocentric retrospective descriptive study that included patients with Undifferentiated endometrial sarcoma treated at Salah Azaiez Institute between 2000 and 2022.

Results Eight patients were included. The mean age was 58 years. The FIGO distribution was : stage I in 2 patients, stage II in one patient, stage III in 2 patients and stage IV in three patients. 2 patients had lung metastases and one patient had peritoneal metastases. Surgery was performed in 6 patients. Five patients underwent R0 resection and one patient an R1 resection. Radiation therapy was performed in one patient. Four patients underwent adjuvant chemotherapy. After a median follow up of 6 months, only one patient is still alive. Six patients had a disease progression and died. Ifosfamide-induced encephalopathy was observed in one patient who died few days after this high grade toxicity.

Conclusion Undifferentiated endometrial sarcoma is an aggressive cancer that in most cases shows rapid progression even after surgery. Referring patients to expert sarcoma centers is highly recommended due to the rarity and complexity of this neoplasm.

Disclosures The authors have no conflicts of interest to declare.